Zhengxiang Gu
Overview
Explore the profile of Zhengxiang Gu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Behforouz M, Cai W, Mohammadi F, Stocksdale M, Gu Z, Ahmadian M, et al.
Bioorg Med Chem
. 2006 Oct;
15(1):495-510.
PMID: 17035024
A series of 7-N-acyllavendamycins with zero, one or two substituents at the C-2', C-3', and C-11' were synthesized through short and efficient methods. Pictet-Spengler condensation of 7-N-acylamino-2-formylquinoline-5,8-diones with tryptamine or...
22.
Weinstein D, Liu W, Gu Z, Langevine C, Ngu K, Fadnis L, et al.
Bioorg Med Chem Lett
. 2005 Feb;
15(5):1435-40.
PMID: 15713402
A series of inhibitors of mammalian 15-lipoxygenase based on tryptamine and homotryptamine scaffolds is described. Compounds with aryl substituents at C-2 of the indole core of tryptamine and homotryptamine sulfonamides...
23.
Murugesan N, Gu Z, Fadnis L, Tellew J, Baska R, Yang Y, et al.
J Med Chem
. 2005 Jan;
48(1):171-9.
PMID: 15634011
In a previous report we demonstrated that merging together key structural elements present in an AT(1) receptor antagonist (1, irbesartan) with key structural elements in a biphenylsulfonamide ET(A) receptor antagonist...
24.
Kowala M, Murugesan N, Tellew J, Carlson K, Monshizadegan H, Ryan C, et al.
J Pharmacol Exp Ther
. 2004 Jan;
309(1):275-84.
PMID: 14718594
Angiotensin II and endothelin-1 activate their respective AT(1) and ET(A) receptors on vascular smooth muscle cells, producing vasoconstriction, and both peptides are implicated in the pathogenesis of essential hypertension. Angiotensin...
25.
Tellew J, Baska R, Beyer S, Carlson K, Cornelius L, Fadnis L, et al.
Bioorg Med Chem Lett
. 2003 Mar;
13(6):1093-6.
PMID: 12643919
A series of 4'-[(imidazol-1-yl)methyl]biphenylsulfonamides has potent antagonist activity against both angiotensin II AT(1) and endothelin ET(A) receptors. Such dual-acting antagonists could have utility in the treatment of hypertension, heart failure,...
26.
Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, et al.
J Med Chem
. 2002 Dec;
46(1):125-37.
PMID: 12502366
We have previously disclosed the selective ET(A) receptor antagonist N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide (1, BMS-193884) as a clinical development candidate. Additional SAR studies at the 2'-position of 1 led to the identification of...
27.
Murugesan N, Tellew J, Gu Z, Kunst B, Fadnis L, Cornelius L, et al.
J Med Chem
. 2002 Aug;
45(18):3829-35.
PMID: 12190306
The ET(A) receptor antagonist (2) (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)-[1,1'-biphenyl]-2-sulfonamide, BMS-193884) shares the same biphenyl core as a large number of AT(1) receptor antagonists, including irbesartan (3). Thus, it was hypothesized that merging the...
28.
Murugesan N, Gu Z, Stein P, Spergel S, Bisaha S, Liu E, et al.
Bioorg Med Chem Lett
. 2002 Feb;
12(4):517-20.
PMID: 11844662
A number of 4'-heterocyclic biphenylsulfonamide derivatives, formally derived from BMS-193884 (1) by replacing the oxazole ring with other heterocyclic rings, are potent and selective endothelin A (ET(A)) receptor antagonists. Among...